

RESEARCH

BOB ECONOMICS RESEARCH | WPI

WPI inflation slows

TECH MAHINDRA | TARGET: Rs 1,539 | +5% | HOLD

Steady progress towards its FY27 margin goal

ICICI PRUDENTIAL LIFE | TARGET: Rs 736 | +23% | BUY

VNB margin expands, focus remains on growing absolute VNB

PERSISTENT SYSTEMS | TARGET: Rs 3,694 | -31% | SELL

Margin beat, TCV/ACV strong. Valuation challenging

SUMMARY

INDIA ECONOMICS: WPI

WPI inflation eased to 0.1% in Sep'25 following 1.9% increase in Sep'24 and 0.5% in Aug'25. Compared with last year (Sep'24), softening in prices was helped by food inflation. On the other hand, fuel and power inflation fell at a slower pace, while manufactured product inflation increased. Core inflation also inched higher to 1.8% in Sep'25 from 0% in Sep'24. Within food, vegetable, fruits and spices helped drag the index down, while protein (eggs, meat and fish) and milk inflation increased.

[Click here](#) for the full report.

TECH MAHINDRA

- Midway through its 3-year journey, TML is on track to achieve its margin goals despite demand environment not being supportive
- TML stated that while FY27 may be better off than FY26 in revenue growth, it does not appear as strong as when the journey began
- Broadly maintain estimates, Target PE multiple and rating. Believe consensus is still skeptical of TML hitting the 15% goal in FY27

[Click here](#) for the full report.



ICICI PRUDENTIAL LIFE

- VNB margin expands by 103bps YoY in Q2FY26, aided by favourable product mix and cost rationalization
- The company reiterated that the impact of GST rate cut and the changes in ITC on EV would be ~1%
- Maintain BUY with TP of Rs 736 (earlier Rs 801), 1.6x its Sept'27 P/EV, on stable performance in future

[Click here](#) for the full report.

PERSISTENT SYSTEMS

- 2QFY26 performance was strong. Growth leader among the Tier-2. And very consistent. Margins outperformed on lower Software cost
- Likely to reach its US\$2bn revenue goal in FY27. 200-300bps EBIT margin expansion may be slight bit of a challenge
- Believe current PE multiple excessive. Believe Margin expansion from here will be anemic. Maintain estimates and Target PE. Retain Sell

[Click here](#) for the full report.

WPI

14 October 2025

WPI inflation slows

WPI inflation eased to 0.1% in Sep'25 following 1.9% increase in Sep'24 and 0.5% in Aug'25. Compared with last year (Sep'24), softening in prices was helped by food inflation. On the other hand, fuel and power inflation fell at a slower pace, while manufactured product inflation increased. Core inflation also inched higher to 1.8% in Sep'25 from 0% in Sep'24. Within food, vegetable, fruits and spices helped drag the index down, while protein (eggs, meat and fish) and milk inflation increased.

Sonal Badhan
Economist

Food grain inflation remains subdued, led by pulses. Amongst cereals, paddy prices have declined even more in Sep'25. Under manufactured products, basis metals, other manufacturing and other transport equipment led inflation higher. Within basic metals, aluminium and copper are facing upward pressure (in contrast to international prices). Slower pace of deflation in fuel inflation was driven by mineral oil index, tracking trend in international oil prices. However, more recently, oil prices have been cooling down, which could have positive impact on headline WPI as well. Going forward, international commodity prices may come down, given revival in trade tensions between US and China and the impact of government shutdown on US economy.

Food inflation remains on downward trajectory:

Headline WPI inflation was at 0.1% in Sep'25 versus at 1.9% in Sep'24 and 0.5% in Aug'25. Compared to last year (Sep'24), food inflation contracted again by (-) 2% versus 9.8% in Sep'24. Vegetable inflation index declined for the 8th consecutive month in Sep'25, and fell by (-) 24.4%, much sharper than 49% increase noted during the same period last year. This was helped by decline in index for potato, onion, tomato, cabbage, cucumber and bitter gourd etc. Index for spices and condiments (-16.9% versus -4.3%) and fruits (-4.1% versus 12.2%) too declined. On the other hand, index for milk (3% versus 2.9%) and eggs, meat and fish (1.3% versus -0.9%) inched up. Food grain inflation remained lower, as the index declined in Sep'25 (-3.8% versus 9.4%), led by sharp decline in inflation index for pulses (-17.2% versus 12.9%). Cereals also registered deflation, mainly due to movement in paddy inflation (-1.5% versus 8.8% in Sep'24). Wheat inflation eased less sharply (3.0% versus 7.7%). Comparing cereal prices on a global level (World Bank's pink sheet) shows that domestic prices are following international trend. Paddy prices internationally have fallen by (-) 34.5% in Sep'25, versus (-) 7.1% decline noted in Sep'24. Wheat prices on the other hand are falling at a slower pace (-9.9% versus -10.3%).



HOLD

TP: Rs 1,539 | ▲ 5%

TECH MAHINDRA

| IT Services

| 15 October 2025

Steady progress towards its FY27 margin goal

- Midway through its 3-year journey, TML is on track to achieve its margin goals despite demand environment not being supportive
- TML stated that while FY27 may be better off than FY26 in revenue growth, it does not appear as strong as when the journey began
- Broadly maintain estimates, Target PE multiple and rating. Believe consensus is still skeptical of TML hitting the 15% goal in FY27

Midway through its 3-year journey more confident on margins than on the revenue growth part: It had set itself the goal of achieving 15% EBIT margin and peer set beating revenue growth in FY27. Six quarters into the journey, the new management seems to be more confident about the margin part than the revenue part. While it stated that it expects both industry and Tech Mahindra (TML) to grow faster in FY27 versus FY26, it does not expect a sharp pick up.

2QFY26 broadly in line: 1.6% QoQ CC growth (strongest in the last 10 quarters) was in line while 12.1% EBIT margin was 60bps stronger than our estimate. Growth QoQ was driven by manufacturing, BFSI and Retail, logistics and transport verticals. Communication and Technology, Media and Entertainment (TME) verticals were drags.

TCV is at the upper end of guidance: US\$815mn is flat QoQ but up 35% YoY and is at the upper end of the US\$600-800mn range indicated by TML. This number (all of it net new) is commendable considering the muted demand environment. It should also be seen in the context of new management's emphasis on better quality deals from both a margin and risk perspective to deliver consistent and profitable growth.

Not much impact from H1-B: TML stated that only 1% of its employee base and 30% of its US employees are on H1-B visas and it does not see a material impact on it from the issue.

AI – has better credentials than some its peers: It is the only Indian company working on LLMs, has 300 plus AI agents and Tech M Orion, the AI platform – all of which we believe has created a differentiated positioning.

Consensus still does not expect TML to deliver 15% EBIT margin in FY27: We think that is quite possible through the various internal initiatives that the company has taken despite the demand environment not being as supportive as was initially planned.

Girish Pai
Research Analyst
Lopa Notaria, CFA
Research Associate
research@bobcaps.in

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	TECHM IN/Rs 1,468
Market cap	US\$ 14.7bn
Free float	65%
3M ADV	US\$ 31.1mn
52wk high/low	Rs 1,808/Rs 1,209
Promoter/FPI/DII	35%/23%/32%


Source: NSE | Price as of 14 Oct 2025

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	529,883	557,391	602,552
EBITDA (Rs mn)	69,911	86,941	112,323
Adj. net profit (Rs mn)	42,818	54,001	74,787
Adj. EPS (Rs)	47.8	61.2	84.8
Consensus EPS (Rs)	47.8	59.6	74.1
Adj. ROAE (%)	15.8	19.7	26.8
Adj. P/E (x)	30.7	24.0	17.3
EV/EBITDA (x)	19.7	15.8	12.3
Adj. EPS growth (%)	80.6	28.0	38.5

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY

TP: Rs 736 | ▲ 23%

ICICI PRUDENTIAL LIFE

| Insurance

| 15 October 2025

VNB margin expands, focus remains on growing absolute VNB

- VNB margin expands by 103bps YoY in Q2FY26, aided by favourable product mix and cost rationalization
- The company reiterated that the impact of GST rate cut and the changes in ITC on EV would be ~1%
- Maintain BUY with TP of Rs 736 (earlier Rs 801), 1.6x its Sept'27 P/EV, on stable performance in future

VNB margin continues to expand: ICICI Pru Life reported VNB margin at 24.44% in Q2FY26 vs 23.41% in Q2FY25, an increase of 103bps YoY, vs 24.52% in Q1FY26. This was largely driven by favourable product mix and cost rationalisation. Share of protection in the product mix, which is the most profitable (high margin) segment increased significantly to 17.3% vs 16.8% in Q2FY25, an expansion of 49bps YoY (up 194bps YoY in H1FY26). Additionally, its share in non-linked and group grew by 300bps YoY and 330bps YoY respectively in Q2FY26. However, the margin expansion was partly offset by decline in the annuity share by ~390bps YoY. Absolute VNB was largely flat (up 1% YoY) in Q2FY26 at Rs 5,920 mn. The company reiterated its continued focus on driving absolute VNB growth.

Impact of GST rate cut: Key discussion revolved around the GST rate cut and the changes in input tax credit (ITC), along with its potential impact on the business. Following the implementation of GST rate cut on Sep 22, 2025, several questions emerged regarding its effect on EV, VNB, commission renegotiations, and possible product-level changes. The management, however, did not provide a definitive response. It reiterated that the estimated impact on EV is likely to be ~1%, which has been factored into the H1FY26 EV of Rs 505.01 bn. Since the GST rate cut was effective for only the last seven days of September, the immediate impact was limited, and IPRU continues to witness healthy policy sales. Additionally, management mentioned that discussions with distributors regarding commission payouts are ongoing. IPRU expects the full impact of GST rate cut to be reflected in the full-year EV through assumption changes.

Maintain BUY on IPRU: The company witnessed pressure on business growth owing to disallowance of ITC which the management believes is a long-term positive despite short term pressure. Some impact was therefore reflected in the VNB and EV for H1FY26, while the full impact is expected to be captured in the full-year EV. Further, with ongoing active commission renegotiations and continued cost optimisation efforts, it expects its margins to improve, aided by favourable product mix. Hence, we maintain BUY on IPRU with TP of Rs 736 (earlier Rs 801), implying 1.6x its Sept'27 P/EV.

Vijiya Rao

Research Analyst

Niraj Jalan

Research Analyst

research@bobcaps.in

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	IPRU IN/Rs 598
Market cap	US\$ 9.7bn
Free float	27%
3M ADV	US\$ 8.3mn
52wk high/low	Rs 777/Rs 526
Promoter/FPI/DII	73%/15%/12%


Source: NSE | Price as of 14 Oct 2025

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
NBP (Rs mn)	2,32,306	2,41,085	2,79,659
APE (Rs mn)	1,04,070	1,10,835	1,28,568
VNB (Rs mn)	23,700	26,489	31,113
Embedded Value (Rs mn)	4,79,510	5,44,447	6,19,332
VNB margin (%)	22.8	23.9	24.2
EVPS (Rs)	332.3	377.7	430.9
EPS (Rs)	8.2	11.0	13.3
Consensus EPS (Rs)	-	-	-
P/EV (x)	1.8	1.6	1.4

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



SELL**TP: Rs 3,694 | ▼ 31%****PERSISTENT SYSTEMS**

| IT Services

| 15 October 2025

Margin beat, TCV/ACV strong. Valuation challenging

- **2QFY26 performance was strong. Growth leader among the Tier-2. And very consistent. Margins outperformed on lower Software cost**
- **Likely to reach its US\$2bn revenue goal in FY27. 200-300bps EBIT margin expansion may be slight bit of a challenge**
- **Believe current PE multiple excessive. Believe Margin expansion from here will be anemic. Maintain estimates and Target PE. Retain Sell**

Girish Pai
Research Analyst
Lopa Notaria, CFA
Research Associate
 research@bobcaps.in

Strong 2QFY26 performance: Delivered 4.4% QoQ CC revenue growth (our estimate 4%). Driven by strong growth in BFSI and healthcare. EBIT margin at 16.3%, a positive surprise (our estimate 15.5%) on the back of lower software license costs (+80bps QoQ).

Strong execution along with AI capabilities seem to be driving out performance: Strong execution on both delivery as well as sales fronts and the SASVA platform (backed by 75 patents) seem to be the key differentiator that has led to PSYS delivering Tier-2 leading revenue growth and margins.

Cost takeout and vendor consolidation deals will impact margins for Tier-2 players: With very little discretionary spending and the market largely driven by cost take out and vendor consolidation driven deals and clients wanting to work with vendors who can provide multi-tower services at the lowest cost, Tier-2 players like PSYS are at small disadvantage. This will force them to bid aggressively, impacting margins. This is already visible in the form of delayed salary hike in FY26, keeping utilization (including trainees) high at ~88-89%, reversing some of its earn out provisions (FY25), changing depreciation policy (FY25), etc.

Margin may not be a big lever to drive EPS growth from here on: Believe EBIT margins at 15-16% are high when compared to its peer set (which are at 13-15%) and even some of the Tier-1 companies. EPS growth, which benefited from margin expansion during the last 5 years, will now be solely dependent on revenue growth

At 42x valuation is not appealing: We broadly maintain estimates for FY27/FY28 and attach a 23.8x Sept 27 EPS to arrive at TP of Rs3694. The 23.8x is at a 25% premium to the target PE multiple given to TCS, our industry benchmark. At 42x 12 forward multiple believe the valuation is excessive and the street is being over optimistic about its earnings prospects in the medium to long term.

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	PSYS IN/Rs 5,338
Market cap	US\$ 9.4bn
Free float	68%
3M ADV	US\$ 30.9mn
52wk high/low	Rs 6,789/Rs 4,149
Promoter/FPI/DII	31%/21%/31%


Source: NSE | Price as of 14 Oct 2025

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	119,387	144,728	173,993
EBITDA (Rs mn)	20,581	27,038	32,872
Adj. net profit (Rs mn)	14,001	18,236	21,917
Adj. EPS (Rs)	90.2	116.7	140.2
Consensus EPS (Rs)	90.2	113.2	137.4
Adj. ROAE (%)	24.8	26.3	26.8
Adj. P/E (x)	59.2	45.8	38.1
EV/EBITDA (x)	40.8	31.1	25.8
Adj. EPS growth (%)	26.7	29.3	20.1

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.